Oxford Biomedica PLC Director Dealings / Market Share Purchase (2702S)
22 June 2018 - 9:03PM
UK Regulatory
TIDMOXB
RNS Number : 2702S
Oxford Biomedica PLC
22 June 2018
Director Dealings / Market Share Purchase
Oxford, UK - 22 June 2018: Oxford BioMedica plc ("Oxford
BioMedica" or "the Group") (LSE: OXB), a leading gene and cell
therapy group, today announces that Dr. Lorenzo Tallarigo, Chairman
of the Group, has purchased 262 ordinary shares of 50p each
("Ordinary Shares") in the Company on 22 June 2018 on the London
Stock Exchange at a price of 1019p per share as set out below under
the market share purchase agreement outlined in the Group's
announcement on 15 December 2015.
Under the market share purchase agreement, one-third of Dr.
Tallarigo's fees as Chairman, after tax, are to be used to purchase
ordinary shares in Oxford BioMedica plc on a monthly basis at the
prevailing market price.
Following this purchase Dr. Tallarigo holds 45,881 ordinary
shares representing 0.07% of the Company.
The below notification, made in accordance with the requirements
of the EU Market Abuse Regulation, gives further detail of the
number of Ordinary Shares purchased.
1. Details of the person discharging material
responsibilities/person closely associated
---- ------------------------------------------------------------------
a. Name Lorenzo Tallarigo
---- ------------------------------- ---------------------------------
2. Reason for the notification
---- ------------------------------------------------------------------
a. Position/status Chairman
---- ------------------------------- ---------------------------------
b. Initial notification Initial notification
/amendment
---- ------------------------------- ---------------------------------
3. Details of the issuer, emission allowance,
market participant, auction platform,
auctioneer or auction monitor
---- ------------------------------------------------------------------
a. Name Oxford BioMedica plc
---- ------------------------------- ---------------------------------
b. Legal Entity 213800S1GVQNXQ15K851
Identifier
---- ------------------------------- ---------------------------------
4. Details of the transaction(s); section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii)
each date; and (iv) each place where
transactions have been conducted
---- ------------------------------------------------------------------
a. Description Oxford BioMedica plc Ordinary
of the financial Shares of 50p each
instrument, GB00BDFBVT43
type of instrument
identification
code
---- ------------------------------- ---------------------------------
b. Nature of Purchase of ordinary shares
the transaction
---- ------------------------------- ---------------------------------
c. Currency GBP - British Pound
---- ------------------------------- ---------------------------------
d. Price(s) and Price(s) Volume(s)
volume(s)
---- ------------------------------- ---------------- ---------------
GBP10.19 262
----------------------------------------------------- ---------------
e. Aggregated 262
information GBP10.19
* Aggregated volume GBP2,669.78
* Price
* Aggregated total
---- ------------------------------- ---------------------------------
f. Date of the 2018-06-22
transaction
---- ------------------------------- ---------------------------------
g. Place of the London Stock Exchange, Main
transaction Market (XLON)
---- ------------------------------- ---------------------------------
The issued share capital of the Group is 65,701,066 ordinary 50p
shares.
-Ends-
For further information,
please contact:
Oxford BioMedica plc: Tel: +44 (0)1865
John Dawson, Chief Executive 783 000
Officer
Stuart Paynter, Chief Financial
Officer
Financial and corporate communications Tel: +44 (0)20 3709
enquiries: 5700
Consilium Strategic Communications
Mary-Jane Elliott/Matthew
Neal/Oliver Manser/Laura
Thornton
Notes for editors
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy
group focused on developing life changing treatments for serious
diseases. Oxford BioMedica and its subsidiaries (the "Group") have
built a sector leading lentiviral vector delivery platform
(LentiVector(R)), which the Group leverages to develop in vivo and
ex vivo products both in-house and with partners. The Group has
created a valuable proprietary portfolio of gene and cell therapy
product candidates in the areas of oncology, ophthalmology and CNS
disorders. The Group has also entered into a number of
partnerships, including with Novartis, Bioverativ, Sanofi, Axovant,
Orchard Therapeutics, GC LabCell and Immune Design, through which
it has long-term economic interests in other potential gene and
cell therapy products. Oxford BioMedica is based across several
locations in Oxfordshire, UK and employs more than 320 people.
Further information is available at www.oxfordbiomedica.co.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHUURARWAANUAR
(END) Dow Jones Newswires
June 22, 2018 07:03 ET (11:03 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024